Narrow search
Showing 1 - 10 of 36,065
Cover Image
Comparing Patient Access to Pharmaceuticals in the UK and US
Cohen, Joshua; Cairns, Catherine; Paquette, Cherie; … - In: Applied Health Economics and Health Policy 5 (2006) 3, pp. 177-187
reimbursement and pricing of approved drugs, the so-called fourth and fifth hurdles. Methods: We reviewed 38 National Institute for … approved. Thirdly, we considered whether and when each drug was recommended for reimbursement and use by NICE, and whether … conditions of reimbursement applied. Fourthly, for the subset of FDA-approved drugs, we examined formulary placement, cost …
Persistent link: https://www.econbiz.de/10005590240
Cover Image
New Drugs for Osteoporosis: Comparison of the Costs and Required Returns With Those of Other Drugs Intended for Long-Term Use
Edwards, Martin - In: PharmacoEconomics 15 (1999) 3, pp. 269-278
Specific regulatory guidelines dictate that developing a new drug for osteoporosis will be significantly more expensive and take at least 2 years longer in comparison with other long-term therapies developed using the International Committee on Harmonisation (ICH) general guidelines. Assuming...
Persistent link: https://www.econbiz.de/10005590530
Cover Image
The Selection of Data Sources For Use in Modelling Studies
Nuijten, Mark J.C. - In: PharmacoEconomics 13 (1998) 3, pp. 305-316
Economic analysis has become increasingly important in healthcare in general, and particularly with respect to pharmaceuticals. Therefore, it is vital that the methods used in such evaluations are carefully scrutinised and refined. However, guidelines contain only a limited number of...
Persistent link: https://www.econbiz.de/10005449056
Cover Image
Management of HIV-1 Infection in Children: Special Considerations
Brady, Michael T. - In: Disease Management and Health Outcomes 4 (1998) 2, pp. 73-91
Optimal management of human immunodeficiency virus type 1 (HIV-1)-infected children requires a commitment from the healthcare delivery system, healthcare providers, and affected families and caregivers. When adequate resources are available (as in most industrialised nations), an aggressive...
Persistent link: https://www.econbiz.de/10005448902
Cover Image
Should Antibacterials Be Deregulated?
Rovira, Joan; Figueras, Montserrat; Segu, Josep L. - In: PharmacoEconomics 13 (1998) 5, pp. 499-508
Deregulation of antibacterials is a recurrent topic in the debate on pharmaceutical policy. This article focuses on one aspect of pharmaceutical regulation, namely the requirement of a medical prescription for purchasing antibacterials. However, a strategy of deregulation should not only concern...
Persistent link: https://www.econbiz.de/10005449163
Cover Image
Herbal Remedies: Issues in Licensing and Economic Evaluation
Ashcroft, Darren M.; Li Wan Po, Alain - In: PharmacoEconomics 16 (1999) 4, pp. 321-328
In recent years, the use of alternative therapies has become widespread. In particular, there has been a resurgence in the public's demand for herbal remedies, despite a lack of high-quality evidence to support the use of many of them. Given the increasing pressures to control healthcare...
Persistent link: https://www.econbiz.de/10005405015
Cover Image
A 3-Dimensional View of Access to Licensed and Subsidized Medicines under Single-Payer Systems in the US, the UK, Australia and New Zealand
Ragupathy, Rajan; Aaltonen, Katri; Tordoff, June; … - In: PharmacoEconomics 30 (2012) 11, pp. 1051-1065
licensing bodies and public reimbursement agencies. The present study compares access to licensed and subsidized medicines under …
Persistent link: https://www.econbiz.de/10010579442
Cover Image
The Use of the Bootstrap Statistical Method for the Pharmacoeconomic Cost Analysis of Skewed Data
Desgagne, Alain; Castilloux, Anne-Marie; Angers, … - In: PharmacoEconomics 13 (1998) 5, pp. 487-497
In pharmacoeconomics, the comparison of the costs of 2 different drugs used for the same treatment is of great interest. The problem is especially challenging when the drugs are likely to produce costly adverse effects in a small number of patients, which is often the case. The data are then...
Persistent link: https://www.econbiz.de/10005590319
Cover Image
Recent Advances in the Methods of Cost-Benefit Analysis in Healthcare: Matching the Art to the Science
McIntosh, Emma; Donaldson, Cam; Ryan, Mandy - In: PharmacoEconomics 15 (1999) 4, pp. 357-367
This paper outlines recent advances in the methods of cost-benefit analysis (CBA). Economic evaluations in healthcare can be criticised for, amongst other things, the inappropriate use of incremental cost-effectiveness ratios and the reporting of benefits in terms of cost savings, such as...
Persistent link: https://www.econbiz.de/10005590453
Cover Image
Patient Self-Reports in Pharmacoeconomic Studies: Their Use and Impact on Study Validity
Evans, Christopher; Crawford, Bruce - In: PharmacoEconomics 15 (1999) 3, pp. 241-256
The validity of estimates of resource utilisation based on patient recall has not been firmly established. A comprehensive literature search was conducted to identify studies that used patient self-reports to derive estimates of healthcare resource utilisation, direct nonmedical costs and...
Persistent link: https://www.econbiz.de/10005448987